Boost for biosimilar switching as Finland add its backing
This article was originally published in SRA
Finland's Fimea has become the latest national regulatory agency in the EU to issue a formal statement supporting the switching of patients from a reference biological product to a biosimilar version – and vice versa – on the grounds that there is no evidence that doing so causes any adverse effects1,2.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.